AstraZeneca Wields Amarin Win In FDA Exclusivity Fight
AstraZeneca is wielding a recent court victory by Amarin Pharma in hopes of securing longer exclusivity for triglyceride-reducing drug Epanova, a sign that the ruling carries significant implications for new products...To view the full article, register now.
Already a subscriber? Click here to view full article